Market Place
Sourcing Support
GlycoMimetics: Pivotal Phase 3 Results Of Uproleselan In R/R AML
04 Jun 2024 //
BUSINESSWIRE
GlycoMimetics KOL Event On Uproleselan Phase 3 Data In R/R AML
29 May 2024 //
BUSINESSWIRE
GlycoMimetics reports Phase 3 results for Uproleselan in AML.
06 May 2024 //
BUSINESSWIRE
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan
03 Jan 2024 //
GLOBENEWSWIRE
GlycoMimetics Announces Independent Presentations on Uproleselan
10 Dec 2023 //
BUSINESSWIRE
GlycoMimetics Announces U.S. FDA Clears Study of Uproleselan
15 Jun 2023 //
BUSINESSWIRE
GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer
06 Sep 2022 //
BUSINESSWIRE
Apollomics doses first subject in Phase III AML therapy trial in China
23 Nov 2021 //
CLINICALTRIALSARENA
Apollomics Begins Dosing in Phase 3 Trial in GlycoMimetics’ Uproleselan for AML
23 Nov 2021 //
BUSINESSWIRE
Apollomics Doses First Patient in Phase 3 Clinical Trial with APL-106
22 Nov 2021 //
GLOBENEWSWIRE
GlycoMimetics Completes Enrollment of Phase 3 Trial Evaluating Uproleselan
15 Nov 2021 //
BUSINESSWIRE
GlycoMimetics shares jump 12% after highlighting promising data
23 Sep 2021 //
SEEKINGALPHA
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China
07 Jan 2021 //
GLOBENEWSWIRE
GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown
05 Dec 2020 //
BUSINESSWIRE
Compelling Data on MOA for GlycoMimetics’ Late-stage Clinical Uproleselan
30 Apr 2020 //
BUSINESSWIRE
GlycoMimetics and Apollomics Announce Exclusive Collaboration
07 Jan 2020 //
BUSINESS WIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.